Cannabinoids 10-Year Anniversary
This first quarter of 2026 closes with another key milestone: 10 years since obtaining the first Swissmedic GMP certificate for our Cannabis sativa extract, standardized to 5% CBD (cannabidiol), in 2016.
Over the years, we have steadily expanded our capabilities, obtaining a long series of achievements, including the GMP certification for CBG (cannabigerol) in 2021, the Swissmedic Narcotics License for THC in 2022 and, more recently, the extension of the GMP authorization to all THC products, as well as pure CBD and THC/CBD combinations in 2025.
Looking ahead, we remain strongly focused on advancing research, quality and compliance, building on our strong foundations to shape the future of our industry in a constantly evolving setting.
Stay updated on Linnea’s latest milestones and innovations.
→ Subscribe to our newsletter via the website to receive quarterly updates on our developments, expertise, and global activities: www.linnea.ch Explore our Cannabinoids expertise.
→ Contact our technical and commercial team at [email protected] to discuss your needs and learn more about Linnea SA’s Cannabinoids division.